1
|
Ikhlef L, Yassine M, Chandouri B, Rivière L, Naves T, Dmytruk N, Gachard N, Jauberteau MO, Gallet PF. Targeting the NTSR2/TrkB oncogenic pathway in chronic lymphocytic leukemia. Sci Rep 2024; 14:6084. [PMID: 38480783 PMCID: PMC10937676 DOI: 10.1038/s41598-024-56663-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Accepted: 03/08/2024] [Indexed: 03/17/2024] Open
Abstract
Current therapies that target the B-cell receptor pathway or the inhibition of anti-apoptotic proteins do not prevent the progressive forms of chronic lymphocytic leukemia (CLL), have low long-term efficacy and are subject to therapeutic resistance. Deciphering the mechanisms of leukemic cell survival and searching for new specific targets therefore remain major challenges to improve the management of this disease. It was evidenced that NTSR2 (neurotensin receptor 2), through the recruitment of TRKB (tropomyosin related kinase B), induces survival pathways in leukemic B cells. We have investigated the therapeutic potential of this protein complex as a new target. The binding domain of NTSR2 and TRKB was identified and a peptide targeting the latter was designed. The peptide binds TRKB and efficiently decreases the interaction of the two proteins. It is also effectively internalized by CLL-B cells in which it notably affects Src family kinase signaling and anti-apoptotic proteins levels. It demonstrated a cytotoxic effect both in vitro on the MEC-1 cell line and ex vivo on a cohort of 30 CLL patients. Altogether, these results underline the therapeutic potential of the NTSR2/TRKB protein complex as a target in CLL and open new perspectives for the development of targeted therapies.
Collapse
Affiliation(s)
- Léa Ikhlef
- UMR INSERM 1308, CAPTuR, University of Limoges, 2 rue du Docteur Marcland, 87025, Limoges, France
| | - May Yassine
- UMR INSERM 1308, CAPTuR, University of Limoges, 2 rue du Docteur Marcland, 87025, Limoges, France
| | - Boutaîna Chandouri
- UMR INSERM 1308, CAPTuR, University of Limoges, 2 rue du Docteur Marcland, 87025, Limoges, France
| | - Léa Rivière
- UMR INSERM 1308, CAPTuR, University of Limoges, 2 rue du Docteur Marcland, 87025, Limoges, France
| | - Thomas Naves
- UMR INSERM 1308, CAPTuR, University of Limoges, 2 rue du Docteur Marcland, 87025, Limoges, France
| | - Natalya Dmytruk
- Department of Clinical Hematology, University Hospital of Limoges, Limoges, France
| | - Nathalie Gachard
- Hematology Laboratory, UMR CNRS7276/INSERM 1262, University Hospital of Limoges, Limoges, France
| | - Marie-Odile Jauberteau
- UMR INSERM 1308, CAPTuR, University of Limoges, 2 rue du Docteur Marcland, 87025, Limoges, France
- Immunology Laboratory, University Hospital of Limoges, Limoges, France
| | - Paul-François Gallet
- UMR INSERM 1308, CAPTuR, University of Limoges, 2 rue du Docteur Marcland, 87025, Limoges, France.
| |
Collapse
|
2
|
Li S, Chen X, Chen J, Wu B, Liu J, Guo Y, Li M, Pu X. Multi-omics integration analysis of GPCRs in pan-cancer to uncover inter-omics relationships and potential driver genes. Comput Biol Med 2023; 161:106988. [PMID: 37201441 DOI: 10.1016/j.compbiomed.2023.106988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 03/30/2023] [Accepted: 04/27/2023] [Indexed: 05/20/2023]
Abstract
G protein-coupled receptors (GPCRs) are the largest drug target family. Unfortunately, applications of GPCRs in cancer therapy are scarce due to very limited knowledge regarding their correlations with cancers. Multi-omics data enables systematic investigations of GPCRs, yet their effective integration remains a challenge due to the complexity of the data. Here, we adopt two types of integration strategies, multi-staged and meta-dimensional approaches, to fully characterize somatic mutations, somatic copy number alterations (SCNAs), DNA methylations, and mRNA expressions of GPCRs in 33 cancers. Results from the multi-staged integration reveal that GPCR mutations cannot well predict expression dysregulation. The correlations between expressions and SCNAs are primarily positive, while correlations of the methylations with expressions and SCNAs are bimodal with negative correlations predominating. Based on these correlations, 32 and 144 potential cancer-related GPCRs driven by aberrant SCNA and methylation are identified, respectively. In addition, the meta-dimensional integration analysis is carried out by using deep learning models, which predict more than one hundred GPCRs as potential oncogenes. When comparing results between the two integration strategies, 165 cancer-related GPCRs are common in both, suggesting that they should be prioritized in future studies. However, 172 GPCRs emerge in only one, indicating that the two integration strategies should be considered concurrently to complement the information missed by the other such that obtain a more comprehensive understanding. Finally, correlation analysis further reveals that GPCRs, in particular for the class A and adhesion receptors, are generally immune-related. In a whole, the work is for the first time to reveal the associations between different omics layers and highlight the necessity of combing the two strategies in identifying cancer-related GPCRs.
Collapse
Affiliation(s)
- Shiqi Li
- College of Chemistry, Sichuan University, Chengdu, 610064, China.
| | - Xin Chen
- College of Chemistry, Sichuan University, Chengdu, 610064, China.
| | - Jianfang Chen
- College of Chemistry, Sichuan University, Chengdu, 610064, China.
| | - Binjian Wu
- College of Chemistry, Sichuan University, Chengdu, 610064, China.
| | - Jing Liu
- College of Chemistry, Sichuan University, Chengdu, 610064, China.
| | - Yanzhi Guo
- College of Chemistry, Sichuan University, Chengdu, 610064, China.
| | - Menglong Li
- College of Chemistry, Sichuan University, Chengdu, 610064, China.
| | - Xuemei Pu
- College of Chemistry, Sichuan University, Chengdu, 610064, China.
| |
Collapse
|
3
|
Wu Y, Berisha A, Borniger JC. Neuropeptides in Cancer: Friend and Foe? Adv Biol (Weinh) 2022; 6:e2200111. [PMID: 35775608 DOI: 10.1002/adbi.202200111] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2022] [Revised: 05/31/2022] [Indexed: 01/28/2023]
Abstract
Neuropeptides are small regulatory molecules found throughout the body, most notably in the nervous, cardiovascular, and gastrointestinal systems. They serve as neurotransmitters or hormones in the regulation of diverse physiological processes. Cancer cells escape normal growth control mechanisms by altering their expression of growth factors, receptors, or intracellular signals, and neuropeptides have recently been recognized as mitogens in cancer growth and development. Many neuropeptides and their receptors exist in multiple subtypes, coupling with different downstream signaling pathways and playing distinct roles in cancer progression. The consideration of neuropeptide/receptor systems as anticancer targets is already leading to new biological and diagnostic knowledge that has the potential to enhance the understanding and treatment of cancer. In this review, recent discoveries regarding neuropeptides in a wide range of cancers, emphasizing their mechanisms of action, signaling cascades, regulation, and therapeutic potential, are discussed. Current technologies used to manipulate and analyze neuropeptides/receptors are described. Applications of neuropeptide analogs and their receptor inhibitors in translational studies and radio-oncology are rapidly increasing, and the possibility for their integration into therapeutic trials and clinical treatment appears promising.
Collapse
Affiliation(s)
- Yue Wu
- Cold Spring Harbor Laboratory, One Bungtown Rd, Cold Spring Harbor, NY, 11724, USA
| | - Adrian Berisha
- Cold Spring Harbor Laboratory, One Bungtown Rd, Cold Spring Harbor, NY, 11724, USA
| | - Jeremy C Borniger
- Cold Spring Harbor Laboratory, One Bungtown Rd, Cold Spring Harbor, NY, 11724, USA
| |
Collapse
|
4
|
Sánchez ML, Coveñas R. The Neurotensinergic System: A Target for Cancer Treatment. Curr Med Chem 2021; 29:3231-3260. [PMID: 34711154 DOI: 10.2174/0929867328666211027124328] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 08/19/2021] [Accepted: 08/26/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND The scientific interest regarding the involvement of peptides in cancer has increased in the last years. In tumor cells the overexpression of peptides and their receptors is known and new therapeutic targets for the treatment of cancer have been suggested. The overexpression of the neurotensinergic system has been associated with poor prognosis, tumor size, higher tumor aggressiveness, increased relapse risk and worse sensitivity to chemotherapy agents. OBJECTIVE The aim of this review is to update the findings regarding the involvement of the neurotensinergic system in cancer to suggest anticancer therapeutic strategies targeting this system. The neurotensin (NT) precursor, NT and its receptors (NTR) and the involvement of the neurotensinergic system in lung, breast, prostate, gastric, colon, liver and pancreatic cancers, glioblastoma, neuroendocrine tumors and B-cell leukemia will be mentioned and discussed as well as the signaling pathways mediated by NT. Some research lines to be developed in the future will be suggested such as: molecules regulating the expression of the NT precursor, influence of the diet in the development of tumors, molecules and signaling pathways activated by NT and antitumor therapeutic strategies targeting the neurotensinergic system. CONCLUSION NT, via the NTR, exerts oncogenic (tumor cell proliferation, invasion, migration, angiogenesis) and antiapoptotic effects, whereas NTR antagonists inhibit these effects. NTR expression can be used as a diagnostic tool/therapeutic target and the administration of NTR antagonists as antitumor drugs could be a therapeutic strategy to treat tumors overexpressing NTR.
Collapse
Affiliation(s)
- Manuel Lisardo Sánchez
- University of Salamanca, Laboratory of Neuroanatomy of the Peptidergic Systems (Lab. 14), Institute of Neurosciences of Castilla y León (INCYL), Salamanca. Spain
| | - Rafael Coveñas
- University of Salamanca, Laboratory of Neuroanatomy of the Peptidergic Systems (Lab. 14), Institute of Neurosciences of Castilla y León (INCYL), Salamanca. Spain
| |
Collapse
|
5
|
Kyriatzis G, Bernard A, Bôle A, Pflieger G, Chalas P, Masse M, Lécorché P, Jacquot G, Ferhat L, Khrestchatisky M. Neurotensin receptor 2 is induced in astrocytes and brain endothelial cells in relation to neuroinflammation following pilocarpine-induced seizures in rats. Glia 2021; 69:2618-2643. [PMID: 34310753 DOI: 10.1002/glia.24062] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 06/30/2021] [Accepted: 07/09/2021] [Indexed: 12/14/2022]
Abstract
Neurotensin (NT) acts as a primary neurotransmitter and neuromodulator in the CNS and has been involved in a number of CNS pathologies including epilepsy. NT mediates its central and peripheral effects by interacting with the NTSR1, NTSR2, and Sort1/NTSR3 receptor subtypes. To date, little is known about the precise expression of the NT receptors in brain neural cells and their regulation in pathology. In the present work, we studied the cellular distribution of the NTSR2 protein in the rat hippocampus and questioned whether its expression was modulated in conditions of neuroinflammation using a model of temporal lobe epilepsy induced by pilocarpine. This model is characterized by a rapid and intense inflammatory reaction with reactive gliosis in the hippocampus. We show that NTSR2 protein is expressed in hippocampal astrocytes and its expression increases together with astrocyte reactivity following induction of status epilepticus. NTSR2 immunoreactivity is also increased in astrocytes proximal to blood vessels and their end-feet, and in endothelial cells. Proinflammatory factors such as IL1β and LPS induced NTSR2 mRNA and protein in cultured astroglial cells. Antagonizing NTSR2 with SR142948A decreased NTSR2 expression as well as astroglial reactivity. Together, our results suggest that NTSR2 is implicated in astroglial and gliovascular inflammation and that targeting the NTSR2 receptor may open new avenues in the regulation of neuroinflammation in CNS diseases.
Collapse
Affiliation(s)
- Grigorios Kyriatzis
- Aix-Marseille University, CNRS, INP, Institute of NeuroPhysiopathology, Marseille Cedex, France
| | - Anne Bernard
- Aix-Marseille University, CNRS, INP, Institute of NeuroPhysiopathology, Marseille Cedex, France
| | - Angélique Bôle
- Aix-Marseille University, CNRS, INP, Institute of NeuroPhysiopathology, Marseille Cedex, France
| | - Guillaume Pflieger
- Aix-Marseille University, CNRS, INP, Institute of NeuroPhysiopathology, Marseille Cedex, France
| | - Petros Chalas
- Aix-Marseille University, CNRS, INP, Institute of NeuroPhysiopathology, Marseille Cedex, France
| | - Maxime Masse
- VECT-HORUS, Faculté de Médecine, Marseille Cedex, France
| | | | | | - Lotfi Ferhat
- Aix-Marseille University, CNRS, INP, Institute of NeuroPhysiopathology, Marseille Cedex, France
| | - Michel Khrestchatisky
- Aix-Marseille University, CNRS, INP, Institute of NeuroPhysiopathology, Marseille Cedex, France
| |
Collapse
|
6
|
PD_BiBIM: Biclustering-based biomarker identification in ESCC microarray data. J Biosci 2021. [DOI: 10.1007/s12038-021-00171-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
7
|
Yang D, Zhang X, Li Z, Xu F, Tang C, Chen H. Neuromedin U and neurotensin may promote the development of the tumour microenvironment in neuroblastoma. PeerJ 2021; 9:e11512. [PMID: 34141479 PMCID: PMC8176915 DOI: 10.7717/peerj.11512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 05/04/2021] [Indexed: 12/03/2022] Open
Abstract
Stage 4S neuroblastoma, as defined by the International Neuroblastoma Staging System committee (INSS), is known to regress spontaneously and have a more favourable outcome compared with stage 4 tumours. Comparing the molecular differences between these two stages may provide insights into the progression of neuroblastoma. Our study aimed to explore the molecular differences in the tumour microenvironment (TME) between INSS stage 4S and stage 4 tumours to provide an insight into the mechanisms underlying the biological processes of neuroblastoma. We downloaded the datasets GSE120572 and GSE73517 from the GEO database and pre-processed them using the limma package. CIBERSORT deconvolution agorithm was applied to analyse the differences in 22 infiltrating immune leukocyte subsets between the two stages. We used gene ontology (GO) enrichment analysis to determine the biological process (BP) annotation of differentially expressed genes (DEGs) using the online WebGestalt tool. Hub genes were determined in the STRING database and Cytoscape, and the expression of these genes was verified in the Oncomine database. Then these critical genes were performed survival analysis in TARGET database. We further validated the hub genes using a transwell assay and wound healing assay to detect the function of the genes in the neuroblastoma cell line SK-N-BE(2). GO analysis revealed that the 216 DEGs between stage 4S and stage 4 were enriched in aggressive biological processes. Neuromedin U (NMU) and neurotensin (NTS), which were significantly associated with patients’ overall survival rate, were verified to be elevated in stage 4, and to promote the proliferation and invasion of the SK-N-BE(2) cell. Tumour infiltrating leukocyte analysis showed a high infiltration of regulatory T cells and type 2 tumour-associated macrophages in stage 4 but not in stage 4S. Results of gene co-expression correlation, and the results of previous studies, suggest that NMU and NTS may play certain roles in modulating TME, thus facilitating the progression of neuroblastoma.
Collapse
Affiliation(s)
- Daheng Yang
- Department of Clinical Laboratory, Children's Hospital of Nanjing Medical University, Nanjing, China
| | - Xianwei Zhang
- Department of Clinical Laboratory, Children's Hospital of Nanjing Medical University, Nanjing, China
| | - Zheqian Li
- Department of Clinical Laboratory, Children's Hospital of Nanjing Medical University, Nanjing, China
| | - Fei Xu
- Department of Clinical Laboratory, Children's Hospital of Nanjing Medical University, Nanjing, China
| | - Chenjie Tang
- Wuxi Children's Hospital, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China
| | - Hongbing Chen
- Department of Clinical Laboratory, Children's Hospital of Nanjing Medical University, Nanjing, China
| |
Collapse
|
8
|
Blondy S, Talbot H, Saada S, Christou N, Battu S, Pannequin J, Jauberteau M, Lalloué F, Verdier M, Mathonnet M, Perraud A. Overexpression of sortilin is associated with 5-FU resistance and poor prognosis in colorectal cancer. J Cell Mol Med 2021; 25:47-60. [PMID: 33325631 PMCID: PMC7810928 DOI: 10.1111/jcmm.15752] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 06/30/2020] [Accepted: 07/30/2020] [Indexed: 02/06/2023] Open
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide. Even if 5-fluorouracil (5-FU) is used as the first-line chemotherapeutic drug, responsiveness is only 20-30%. Acquired resistance to 5-FU contributes to both poor patient prognosis and relapse, emphasizing the need to identify biomarkers. Sortilin, a vacuolar protein sorting 10 protein (Vps10p), implicated in protein trafficking, is over expressed in CRC cell lines cultured 72 hours in presence of 5-FU. This overexpression was also observed in 5-FU-resistant cells derived from these cell lines as well as in CRC primary cultures (or patients derived cell lines). A significantly higher expression of sortilin was observed in vivo, in 5-FU-treated tumours engrafted in Nude mice, as compared with non-treated tumour. A study of transcriptional regulation allowed identifying a decrease in ATF3 expression, as an explanation of sortilin overexpression following 5-FU treatment. In silico analysis revealed SORT1 expression correlation with poor prognosis. Moreover, sortilin expression was found to be positively correlated with CRC tumour grades. Collectively, our findings identify sortilin as a potential biomarker of 5-FU resistance associated with poor clinical outcomes and aggressiveness in CRC. As a new prognostic factor, sortilin expression could be used to fight against CRC.
Collapse
MESH Headings
- Adaptor Proteins, Vesicular Transport/genetics
- Adaptor Proteins, Vesicular Transport/metabolism
- Aged
- Aged, 80 and over
- Animals
- Cell Line, Tumor
- Colorectal Neoplasms/drug therapy
- Colorectal Neoplasms/genetics
- Colorectal Neoplasms/pathology
- Disease-Free Survival
- Drug Resistance, Neoplasm/drug effects
- Drug Resistance, Neoplasm/genetics
- Female
- Fluorouracil/therapeutic use
- Gene Expression Regulation, Neoplastic/drug effects
- Humans
- Male
- Mice, Nude
- Neoplasm Grading
- Prognosis
- Protein Transport/drug effects
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Treatment Outcome
- Xenograft Model Antitumor Assays
- Mice
Collapse
Affiliation(s)
- Sabrina Blondy
- Laboratoire EA3842 Contrôle de l’Activation CellulaireProgression Tumorale et Résistances thérapeutiques «CAPTuR»Faculté de médecineLimogesFrance
| | - Hugo Talbot
- Laboratoire EA3842 Contrôle de l’Activation CellulaireProgression Tumorale et Résistances thérapeutiques «CAPTuR»Faculté de médecineLimogesFrance
| | - Sofiane Saada
- Laboratoire EA3842 Contrôle de l’Activation CellulaireProgression Tumorale et Résistances thérapeutiques «CAPTuR»Faculté de médecineLimogesFrance
| | - Niki Christou
- Laboratoire EA3842 Contrôle de l’Activation CellulaireProgression Tumorale et Résistances thérapeutiques «CAPTuR»Faculté de médecineLimogesFrance
- Service de Chirurgie DigestiveEndocrinienne et GénéraleCHU de LimogesLimogesFrance
| | - Serge Battu
- Laboratoire EA3842 Contrôle de l’Activation CellulaireProgression Tumorale et Résistances thérapeutiques «CAPTuR»Faculté de médecineLimogesFrance
| | - Julie Pannequin
- IGFUniversité MontpellierCNRSINSERMMontpellier Cedex 5France
| | - Marie‐Odile Jauberteau
- Laboratoire EA3842 Contrôle de l’Activation CellulaireProgression Tumorale et Résistances thérapeutiques «CAPTuR»Faculté de médecineLimogesFrance
- Service d’ImmunologieCHU de LimogesLimogesFrance
| | - Fabrice Lalloué
- Laboratoire EA3842 Contrôle de l’Activation CellulaireProgression Tumorale et Résistances thérapeutiques «CAPTuR»Faculté de médecineLimogesFrance
| | - Mireille Verdier
- Laboratoire EA3842 Contrôle de l’Activation CellulaireProgression Tumorale et Résistances thérapeutiques «CAPTuR»Faculté de médecineLimogesFrance
| | - Muriel Mathonnet
- Laboratoire EA3842 Contrôle de l’Activation CellulaireProgression Tumorale et Résistances thérapeutiques «CAPTuR»Faculté de médecineLimogesFrance
- Service de Chirurgie DigestiveEndocrinienne et GénéraleCHU de LimogesLimogesFrance
| | - Aurélie Perraud
- Laboratoire EA3842 Contrôle de l’Activation CellulaireProgression Tumorale et Résistances thérapeutiques «CAPTuR»Faculté de médecineLimogesFrance
- Service de Chirurgie DigestiveEndocrinienne et GénéraleCHU de LimogesLimogesFrance
| |
Collapse
|
9
|
Christou N, Blondy S, David V, Verdier M, Lalloué F, Jauberteau MO, Mathonnet M, Perraud A. Neurotensin pathway in digestive cancers and clinical applications: an overview. Cell Death Dis 2020; 11:1027. [PMID: 33268796 PMCID: PMC7710720 DOI: 10.1038/s41419-020-03245-8] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 11/01/2020] [Accepted: 11/02/2020] [Indexed: 02/06/2023]
Abstract
Initially, NEUROTENSIN (NTS) has been shown to play physiological and biological functions as a neuro-transmitter/modulator in the central nervous system and as an endocrine factor in the periphery, through its binding to two kinds of receptors: NTSR1 and 2 (G protein-coupled receptors) and NTSR3/sortilin (a vacuolar protein-sorting 10-domain receptor). NTS also plays oncogenic roles in many types of cancer, including digestive cancers. In tumor tissues, NTS and NTSR1 expression is higher than in healthy ones and is associated with poor prognosis. NTS and NTRS1 promote cancer progression and play key functions in metastatic processes; they modulate several signaling pathways and they contribute to changes in the tumor microenvironment. Conversely, NTRS2 involvement in digestive cancers is poorly understood. Discovered for mediating NTS biological effects, sortilin recently emerged as a promising target as its expression was found to be increased in various types of cancers. Because it can be secreted, a soluble form of sortilin (sSortilin) appears as a new serum biomarker which, on the basis of recent studies, promises to be useful in both the diagnosis and tumor progression monitoring. More precisely, it appears that soluble sortilin can be associated with other receptors like TRKB. These associations occur in exosomes and trigger the aggressiveness of cancers like glioblastoma, leading to the concept of a possible composite theranostic biomarker. This review summarizes the oncogenic roles of the NTS signaling pathways in digestive cancers and discusses their emergence as promising early diagnostic and/or prognostic biomarkers and therapeutic targets.
Collapse
Affiliation(s)
- Niki Christou
- Laboratoire EA3842 CAPTuR « Contrôle de l'Activation cellulaire, Progression Tumorale et Résistances thérapeutiques », Faculté de médecine, 2 rue du Docteur Marcland, 87025, Limoges, France.
- Service de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, 2 avenue Martin Luther King, 87042, Limoges, France.
| | - Sabrina Blondy
- Laboratoire EA3842 CAPTuR « Contrôle de l'Activation cellulaire, Progression Tumorale et Résistances thérapeutiques », Faculté de médecine, 2 rue du Docteur Marcland, 87025, Limoges, France
| | - Valentin David
- Laboratoire EA3842 CAPTuR « Contrôle de l'Activation cellulaire, Progression Tumorale et Résistances thérapeutiques », Faculté de médecine, 2 rue du Docteur Marcland, 87025, Limoges, France
- Service de Pharmacie, CHU de Limoges, 2 avenue Martin Luther King, 87042, Limoges, France
| | - Mireille Verdier
- Laboratoire EA3842 CAPTuR « Contrôle de l'Activation cellulaire, Progression Tumorale et Résistances thérapeutiques », Faculté de médecine, 2 rue du Docteur Marcland, 87025, Limoges, France
| | - Fabrice Lalloué
- Laboratoire EA3842 CAPTuR « Contrôle de l'Activation cellulaire, Progression Tumorale et Résistances thérapeutiques », Faculté de médecine, 2 rue du Docteur Marcland, 87025, Limoges, France
| | - Marie-Odile Jauberteau
- Laboratoire EA3842 CAPTuR « Contrôle de l'Activation cellulaire, Progression Tumorale et Résistances thérapeutiques », Faculté de médecine, 2 rue du Docteur Marcland, 87025, Limoges, France
- Service d'Immunologie, CHU de Limoges, 2 avenue Martin Luther King, 87042, Limoges, France
| | - Muriel Mathonnet
- Laboratoire EA3842 CAPTuR « Contrôle de l'Activation cellulaire, Progression Tumorale et Résistances thérapeutiques », Faculté de médecine, 2 rue du Docteur Marcland, 87025, Limoges, France
- Service de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, 2 avenue Martin Luther King, 87042, Limoges, France
| | - Aurélie Perraud
- Laboratoire EA3842 CAPTuR « Contrôle de l'Activation cellulaire, Progression Tumorale et Résistances thérapeutiques », Faculté de médecine, 2 rue du Docteur Marcland, 87025, Limoges, France
- Service de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, 2 avenue Martin Luther King, 87042, Limoges, France
| |
Collapse
|
10
|
Fanelli R, Chastel A, Previti S, Hindié E, Vimont D, Zanotti-Fregonara P, Fernandez P, Garrigue P, Lamare F, Schollhammer R, Balasse L, Guillet B, Rémond E, Morgat C, Cavelier F. Silicon-Containing Neurotensin Analogues as Radiopharmaceuticals for NTS1-Positive Tumors Imaging. Bioconjug Chem 2020; 31:2339-2349. [DOI: 10.1021/acs.bioconjchem.0c00419] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Roberto Fanelli
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| | - Adrien Chastel
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Santo Previti
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| | - Elif Hindié
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Delphine Vimont
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
| | | | - Philippe Fernandez
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Philippe Garrigue
- Aix-Marseille University, INSERM, Institut National de la Recherche Agronomique, Centre de Recherche en Cardiovasculaire et Nutrition, Marseille 13385, France
- Aix-Marseille University, Centre Européen de Recherche en Imagerie Médicale, Marseille 13005, France
| | - Frédéric Lamare
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Romain Schollhammer
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Laure Balasse
- Aix-Marseille University, INSERM, Institut National de la Recherche Agronomique, Centre de Recherche en Cardiovasculaire et Nutrition, Marseille 13385, France
| | - Benjamin Guillet
- Aix-Marseille University, INSERM, Institut National de la Recherche Agronomique, Centre de Recherche en Cardiovasculaire et Nutrition, Marseille 13385, France
- Aix-Marseille University, Centre Européen de Recherche en Imagerie Médicale, Marseille 13005, France
| | - Emmanuelle Rémond
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| | - Clément Morgat
- University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux F-33000, France
- Nuclear Medicine Department, University Hospital of Bordeaux, Bordeaux F-33000, France
| | - Florine Cavelier
- Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, CNRS, Université de Montpellier, ENSCM, Place Eugène Bataillon, Montpellier 34095 Cedex 5, France
| |
Collapse
|
11
|
Talbot H, Saada S, Barthout E, Gallet PF, Gachard N, Abraham J, Jaccard A, Troutaud D, Lalloué F, Naves T, Fauchais AL, Jauberteau MO. BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells. Sci Rep 2020; 10:12572. [PMID: 32724091 PMCID: PMC7387561 DOI: 10.1038/s41598-020-69307-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Accepted: 06/22/2020] [Indexed: 02/02/2023] Open
Abstract
Evading apoptosis and sustained survival signaling pathways are two central hallmarks of B-cell chronic lymphocytic leukemia (B-CLL) cells. In this regard, nurse-like cells (NLC), the monocyte-derived type 2 macrophages, deliver stimulatory signals via B-cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), and the C-X-C Motif Chemokine Ligand 12 (CXCL12). Previously, we demonstrated that brain-derived neurotrophic factor (BDNF) protects B-CLL cells from spontaneous apoptosis by activating the oncogenic complex NTSR2-TrkB (neurotensin receptor 2-tropomyosin-related kinase receptor B), only overexpressed in B-CLL cells, inducing anti-apoptotic protein Bcl-2 (B-cell lymphoma 2) expression and Src kinase survival signaling pathways. Herein, we demonstrate that BDNF belongs to the NLC secretome and promotes B-CLL survival. This was demonstrated in primary B-CLL co-cultured with their autologous NLC, compared to B-CLL cells cultured alone. Inhibition of BDNF in co-cultures, enhances B-CLL apoptosis, whereas its exogenous recombinant activates pro-survival pathways in B-CLL cultured alone (i.e. Src activation and Bcl-2 expression), at a higher level than those obtained by the exogenous recombinant cytokines BAFF, APRIL and CXCL12, the known pro-survival cytokines secreted by NLC. Together, these results showed that BDNF release from NLC trigger B-CLL survival. Blocking BDNF would support research strategies against pro-survival cytokines to limit sustained B-CLL cell survival.
Collapse
Affiliation(s)
- Hugo Talbot
- Equipe Accueil 3842 CAPTuR, Faculty of Medicine, Limoges University, 2, Rue du Docteur Marcland, 87025, Limoges Cedex, France
| | - Sofiane Saada
- Equipe Accueil 3842 CAPTuR, Faculty of Medicine, Limoges University, 2, Rue du Docteur Marcland, 87025, Limoges Cedex, France
| | - Elodie Barthout
- Equipe Accueil 3842 CAPTuR, Faculty of Medicine, Limoges University, 2, Rue du Docteur Marcland, 87025, Limoges Cedex, France
| | - Paul-François Gallet
- Equipe Accueil 3842 CAPTuR, Faculty of Medicine, Limoges University, 2, Rue du Docteur Marcland, 87025, Limoges Cedex, France
| | - Nathalie Gachard
- Hematology Laboratory, Dupuytren Hospital University Center of Limoges, Limoges Cedex, France.,CNRS-UMR 7276, Limoges University, Limoges Cedex, France
| | - Julie Abraham
- CNRS-UMR 7276, Limoges University, Limoges Cedex, France.,Department of Hematology, Dupuytren Hospital University Center of Limoges, Limoges Cedex, France
| | - Arnaud Jaccard
- CNRS-UMR 7276, Limoges University, Limoges Cedex, France.,Department of Hematology, Dupuytren Hospital University Center of Limoges, Limoges Cedex, France
| | - Danielle Troutaud
- Equipe Accueil 3842 CAPTuR, Faculty of Medicine, Limoges University, 2, Rue du Docteur Marcland, 87025, Limoges Cedex, France
| | - Fabrice Lalloué
- Equipe Accueil 3842 CAPTuR, Faculty of Medicine, Limoges University, 2, Rue du Docteur Marcland, 87025, Limoges Cedex, France
| | - Thomas Naves
- Equipe Accueil 3842 CAPTuR, Faculty of Medicine, Limoges University, 2, Rue du Docteur Marcland, 87025, Limoges Cedex, France
| | - Anne-Laure Fauchais
- Equipe Accueil 3842 CAPTuR, Faculty of Medicine, Limoges University, 2, Rue du Docteur Marcland, 87025, Limoges Cedex, France.,Department of Internal Medicine, Dupuytren Hospital University Center of Limoges, Limoges Cedex, France
| | - Marie-Odile Jauberteau
- Equipe Accueil 3842 CAPTuR, Faculty of Medicine, Limoges University, 2, Rue du Docteur Marcland, 87025, Limoges Cedex, France. .,Department of Immunology, Dupuytren Hospital University Center of Limoges, Limoges Cedex, France.
| |
Collapse
|
12
|
Dao T, Salahuddin S, Charfi C, Sicard AA, Jenabian MA, Annabi B. Pharmacological targeting of neurotensin response by diet-derived EGCG in macrophage-differentiated HL-60 promyelocytic leukemia cells. PHARMANUTRITION 2020. [DOI: 10.1016/j.phanu.2020.100191] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
13
|
Nikolaou S, Qiu S, Fiorentino F, Simillis C, Rasheed S, Tekkis P, Kontovounisios C. The role of Neurotensin and its receptors in non-gastrointestinal cancers: a review. Cell Commun Signal 2020; 18:68. [PMID: 32336282 PMCID: PMC7183616 DOI: 10.1186/s12964-020-00569-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Accepted: 03/27/2020] [Indexed: 12/11/2022] Open
Abstract
Background Neurotensin, originally isolated in 1973 has both endocrine and neuromodulator activity and acts through its three main receptors. Their role in promoting tumour cell proliferation, migration, DNA synthesis has been studied in a wide range of cancers. Expression of Neurotensin and its receptors has also been correlated to prognosis and prediction to treatment. Main body The effects of NT are mediated through mitogen-activated protein kinases, epidermal growth factor receptors and phosphatidylinositol-3 kinases amongst others. This review is a comprehensive summary of the molecular pathways by which Neurotensin and its receptors act in cancer cells. Conclusion Identifying the role of Neurotensin in the underlying molecular mechanisms in various cancers can give way to developing new agnostic drugs and personalizing treatment according to the genomic structure of various cancers. Video abstract
Collapse
Affiliation(s)
- Stella Nikolaou
- Department of Colorectal Surgery, Chelsea and Westminster Hospital, NHS Foundation Trust, London, UK.,Department of Colorectal Surgery, Royal Marsden Hospital, London, UK.,Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Campus, 369 Fulham Road, London, SW10 9NH, UK
| | - Shengyang Qiu
- Department of Colorectal Surgery, Chelsea and Westminster Hospital, NHS Foundation Trust, London, UK.,Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Campus, 369 Fulham Road, London, SW10 9NH, UK
| | - Francesca Fiorentino
- Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Campus, 369 Fulham Road, London, SW10 9NH, UK
| | - Constantinos Simillis
- Department of Colorectal Surgery, Chelsea and Westminster Hospital, NHS Foundation Trust, London, UK
| | - Shahnawaz Rasheed
- Department of Colorectal Surgery, Chelsea and Westminster Hospital, NHS Foundation Trust, London, UK.,Department of Colorectal Surgery, Royal Marsden Hospital, London, UK.,Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Campus, 369 Fulham Road, London, SW10 9NH, UK
| | - Paris Tekkis
- Department of Colorectal Surgery, Chelsea and Westminster Hospital, NHS Foundation Trust, London, UK.,Department of Colorectal Surgery, Royal Marsden Hospital, London, UK.,Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Campus, 369 Fulham Road, London, SW10 9NH, UK
| | - Christos Kontovounisios
- Department of Colorectal Surgery, Chelsea and Westminster Hospital, NHS Foundation Trust, London, UK. .,Department of Colorectal Surgery, Royal Marsden Hospital, London, UK. .,Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Campus, 369 Fulham Road, London, SW10 9NH, UK.
| |
Collapse
|
14
|
Usman S, Khawer M, Rafique S, Naz Z, Saleem K. The current status of anti-GPCR drugs against different cancers. J Pharm Anal 2020; 10:517-521. [PMID: 33425448 PMCID: PMC7775845 DOI: 10.1016/j.jpha.2020.01.001] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Revised: 01/06/2020] [Accepted: 01/10/2020] [Indexed: 12/23/2022] Open
Abstract
G protein coupled receptors (GPCRs) have emerged as the most potential target for a number of drug discovery programs ranging from control of blood pressure, diabetes, cure for genetic diseases to treatment of cancer. A panel of different ligands including hormones, peptides, ions and small molecules is responsible for activation of these receptors. Molecular genetics has identified key GPCRs, whose mutations or altered expressions are linked with tumorgenicity. In this review, we discussed recent advances regarding the involvement of GPCRs in the development of cancers and approaches to manipulating the mechanism behind GPCRs involved tumor growth and metastasis to treat different types of human cancer. This review provides an insight into the current scenario of GPCR-targeted therapy, progress to date and the challenges in the development of anticancer drugs.
Collapse
Affiliation(s)
- Sana Usman
- Centre for Applied Molecular Biology, 87-West Canal Bank Road Thokar Niaz Baig, University of the Punjab, Lahore, Pakistan
| | - Maria Khawer
- Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
| | - Shazia Rafique
- Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
| | - Zara Naz
- Centre for Applied Molecular Biology, 87-West Canal Bank Road Thokar Niaz Baig, University of the Punjab, Lahore, Pakistan
| | - Komal Saleem
- Centre for Applied Molecular Biology, 87-West Canal Bank Road Thokar Niaz Baig, University of the Punjab, Lahore, Pakistan
| |
Collapse
|
15
|
Bentayeb H, Aitamer M, Petit B, Dubanet L, Elderwish S, Désaubry L, de Gramont A, Raymond E, Olivrie A, Abraham J, Jauberteau MO, Troutaud D. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2019; 38:450. [PMID: 31684984 PMCID: PMC6830009 DOI: 10.1186/s13046-019-1440-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 10/04/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND Diffuse large B-cell lymphomas (DLBCLs) are aggressive lymphomas accounting for approximately a third of non-Hodgkin lymphomas. Prohibitin 1 (PHB1) and prohibitin 2 (PHB2) are scaffold proteins that promote mitochondria homeostasis and consequently cell survival, but biological functions of cytoplasmic PHBs remain largely unknown in DLBCL. METHODS PHB expression was analyzed in 82 DLBCL biopsies and five DLBCL cell lines by immunohistochemistry (IHC) and Western blotting. Pharmacological inhibition of PHB using the synthetic flavagline FL3 was realized in vitro to gain insight PHB cellular functions. Effects of FL3 on DLBCL cell line viability, apoptosis, C-Raf-ERK-MNK-eIF4E signaling pathway and eIF4F complex formation and activity were evaluated by XTT assay, annexin V-FITC/PI dual staining and Western blotting respectively. Subcutaneous DLBCL xenograft model in SCID mice was also performed to determine in vivo FL3 effect. RESULTS As in DLBCL cell lines, PHB1 and PHB2 were expressed in germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes. In patient samples, high PHB levels were associated with higher serum LDH (PHB1 and PHB2), IPIaa (PHB2), and Ki-67 (PHB2) expression. Higher PHB1 expression tends to be associated with shorter event-free survival (EFS) in patients, especially in male patients. FL3 induced apoptosis of DLBCL cell lines that was associated with inhibition of the ERK-MNK-eIF4E signaling pathway, including aggressive double/triple-hit DLBCL cell lines. This resulted in altered eIF4F complex formation and activity leading to a reduction of Bcl-2 and c-Myc expression levels. Moreover, FL3 strongly downregulated DLBCL cellular levels of Akt protein and AKT mRNA. FL3 antitumor activity was also confirmed in vivo in a murine xenograft model. CONCLUSION Our data indicate that PHB overexpression is associated with markers of tumor aggressiveness in DLBCL, and that targeting PHBs may be a therapeutic option, notably in aggressive subtypes.
Collapse
Affiliation(s)
| | | | - Barbara Petit
- Laboratoire d'Anatomie-Pathologique, CHU de Limoges, Limoges, France
| | | | | | - Laurent Désaubry
- UMR 7203, CNRS - Université Paris Sorbonne, Paris, France.,Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, 300457, China
| | | | - Eric Raymond
- AFR Oncology, 1 place Paul Verlaine, Boulogne-Billancourt, France.,Groupe Hospitalier Saint-Joseph, Paris, France
| | - Agnès Olivrie
- Service d'Hématologie Clinique, CHU de Limoges, Limoges, France
| | - Julie Abraham
- Service d'Hématologie Clinique, CHU de Limoges, Limoges, France
| | - Marie-Odile Jauberteau
- EA3842, Université de Limoges, Limoges, France.,Service d'Immunologie, CHU Limoges, Limoges, France
| | | |
Collapse
|
16
|
Sun Z, Wang Z, Li L, Yan J, Shao C, Bao Z, Jing L, Pang Q, Geng Y, Zhang L. RAGE/galectin-3 yields intraplaque calcification transformation via sortilin. Acta Diabetol 2019; 56:457-472. [PMID: 30603868 DOI: 10.1007/s00592-018-1273-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 12/10/2018] [Indexed: 12/23/2022]
Abstract
AIMS Macrocalcification and microcalcification present different clinical risks, but the regulatory of their formation was unclear. Therefore, this study explored the underlying mechanisms of macrocalcification and microcalcification in diabetes mellitus. METHODS Anterior tibial arteries of amputated diabetic feet were collected. According to the calcium content, patients were divided into less-calcification group and more-calcification group. And calcification morphology in plaques was observed. For further study, an in vivo mouse diabetic atherosclerosis model and an in vitro primary mouse aortic smooth muscle cell model were established. After the receptors for AGEs (RAGE) or galectin-3 were silenced, calcified nodule sizes and sortilin expression were determined. Scanning electron microscopy (SEM) was performed to detect the aggregation of matrix vesicles with the inhibition or promotion of sortilin. RESULTS Both macro- and microcalcification were found in human anterior tibial artery plaques. Macrocalcification formed after the silencing of RAGE, and microcalcification formed after the silencing of galectin-3. In the process of RAGE- or galcetin-3-induced calcification, sortilin played an important role downstream. SEM showed that sortilin promoted the aggregation of MVs in the early stage of calcification and formed larger calcified nodules. CONCLUSION RAGE downregulated sortilin and then transmitted microcalcification signals, whereas galectin-3 upregulated sortilin, which accelerated the aggregation of MVs in the early stage of calcification and mediated the formation of macrocalcifications, These data illustrate the progression of two calcification types and suggest sortilin as a potential target for early intervention of calcification and as an effective biomarker for the assessment of long-term clinical risk and prognosis.
Collapse
MESH Headings
- Adaptor Proteins, Vesicular Transport/genetics
- Adaptor Proteins, Vesicular Transport/metabolism
- Amputation, Surgical
- Animals
- Aorta/metabolism
- Aorta/pathology
- Blood Proteins
- Cells, Cultured
- Diabetes Mellitus, Experimental/complications
- Diabetes Mellitus, Experimental/metabolism
- Diabetes Mellitus, Experimental/pathology
- Diabetic Angiopathies/genetics
- Diabetic Angiopathies/metabolism
- Diabetic Angiopathies/surgery
- Diabetic Foot/pathology
- Diabetic Foot/surgery
- Galectin 3/physiology
- Galectins
- Gene Expression Regulation/drug effects
- Humans
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Myocytes, Smooth Muscle/metabolism
- Myocytes, Smooth Muscle/pathology
- Plaque, Atherosclerotic/genetics
- Plaque, Atherosclerotic/metabolism
- RNA Interference
- RNA, Small Interfering/pharmacology
- Receptor for Advanced Glycation End Products/physiology
- Signal Transduction/drug effects
- Signal Transduction/genetics
- Streptozocin
- Tibial Arteries/metabolism
- Tibial Arteries/pathology
- Vascular Calcification/genetics
- Vascular Calcification/metabolism
- Vascular Calcification/pathology
Collapse
Affiliation(s)
- Zhen Sun
- Department of Cardiology, Affiliated Hospital of Jiangsu University, 212001, Zhenjiang, China
| | - Zhongqun Wang
- Department of Cardiology, Affiliated Hospital of Jiangsu University, 212001, Zhenjiang, China.
| | - Lihua Li
- Department of Pathology, Affiliated Hospital of Jiangsu University, 212001, Zhenjiang, China
| | - Jinchuan Yan
- Department of Cardiology, Affiliated Hospital of Jiangsu University, 212001, Zhenjiang, China
| | - Chen Shao
- Department of Cardiology, Affiliated Hospital of Jiangsu University, 212001, Zhenjiang, China
| | - Zhengyang Bao
- Department of Cardiology, Affiliated Hospital of Jiangsu University, 212001, Zhenjiang, China
| | - Lele Jing
- Department of Cardiology, Affiliated Hospital of Jiangsu University, 212001, Zhenjiang, China
| | - Qiwen Pang
- Department of Cardiology, Affiliated Hospital of Jiangsu University, 212001, Zhenjiang, China
| | - Yue Geng
- Department of Cardiology, Affiliated Hospital of Jiangsu University, 212001, Zhenjiang, China
| | - Lili Zhang
- Department of Cardiology, Affiliated Hospital of Jiangsu University, 212001, Zhenjiang, China
| |
Collapse
|
17
|
Ouyang Q, Zhou J, Yang W, Cui H, Xu M, Yi L. Oncogenic role of neurotensin and neurotensin receptors in various cancers. Clin Exp Pharmacol Physiol 2018; 44:841-846. [PMID: 28556374 DOI: 10.1111/1440-1681.12787] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Revised: 05/01/2017] [Accepted: 05/17/2017] [Indexed: 12/13/2022]
Abstract
Neurotensin (NTS) has long been recognized as a neurotransmitter or neuromodulator in the central nervous system and as an endocrine agent in the periphery via actions mediated through neurotensin receptors (NTSRs). Many studies support a role for NTS in the endocrine, autocrine and paracrine growth stimulation of cancer, with oncogenic actions described for NTS in different types of cancers and cancer cell lines at each step of cancer progression, ranging from tumour growth and survival to metastatic spread. The mechanisms underlying the effects of the NTS/NTSR system in cell proliferation, migration and invasion, as well as the anti-apoptotic effects of this system, have been elucidated in different types of cancers, and include mitogen-activated protein kinases, phosphatidylinositol 3-kinase and RhoGTPases. The present mini review summarizes recent findings relating to the oncogenic function of the NTS/NTSR system.
Collapse
Affiliation(s)
- Qing Ouyang
- Department of Neurosurgery, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing, China
| | - Ji Zhou
- Department of Neurosurgery, People's Liberation Army (PLA) Rocket Forces General Hospital, Beijing, China
| | - Wei Yang
- Department of Neurosurgery, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing, China
| | - Hongjuan Cui
- State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing, China
| | - Minhui Xu
- Department of Neurosurgery, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing, China
| | - Liang Yi
- Department of Neurosurgery, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing, China
| |
Collapse
|
18
|
Worthington JJ, Reimann F, Gribble FM. Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity. Mucosal Immunol 2018; 11:3-20. [PMID: 28853441 DOI: 10.1038/mi.2017.73] [Citation(s) in RCA: 141] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Accepted: 07/14/2017] [Indexed: 02/06/2023]
Abstract
The intestinal epithelium must balance efficient absorption of nutrients with partitioning commensals and pathogens from the bodies' largest immune system. If this crucial barrier fails, inappropriate immune responses can result in inflammatory bowel disease or chronic infection. Enteroendocrine cells represent 1% of this epithelium and have classically been studied for their detection of nutrients and release of peptide hormones to mediate digestion. Intriguingly, enteroendocrine cells are the key sensors of microbial metabolites, can release cytokines in response to pathogen associated molecules and peptide hormone receptors are expressed on numerous intestinal immune cells; thus enteroendocrine cells are uniquely equipped to be crucial and novel orchestrators of intestinal inflammation. In this review, we introduce enteroendocrine chemosensory roles, summarize studies correlating enteroendocrine perturbations with intestinal inflammation and describe the mechanistic interactions by which enteroendocrine and mucosal immune cells interact during disease; highlighting this immunoendocrine axis as a key aspect of innate immunity.
Collapse
Affiliation(s)
- J J Worthington
- Lancaster University, Faculty of Health and Medicine, Division of Biomedical and Life Sciences, Lancaster, Lancashire, UK
| | - F Reimann
- University of Cambridge, Metabolic Research Laboratories, Wellcome Trust/MRC Institute of Metabolic Science & MRC Metabolic Diseases Unit, Addenbrooke's Hospital, Cambridge, UK
| | - F M Gribble
- University of Cambridge, Metabolic Research Laboratories, Wellcome Trust/MRC Institute of Metabolic Science & MRC Metabolic Diseases Unit, Addenbrooke's Hospital, Cambridge, UK
| |
Collapse
|
19
|
Abbaci A, Talbot H, Saada S, Gachard N, Abraham J, Jaccard A, Bordessoule D, Fauchais AL, Naves T, Jauberteau MO. Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis. Oncogene 2017; 37:756-767. [PMID: 29059151 PMCID: PMC5808079 DOI: 10.1038/onc.2017.365] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Revised: 07/29/2017] [Accepted: 08/25/2017] [Indexed: 02/06/2023]
Abstract
B-cell chronic lymphocytic leukemia (B-CLL) cells are resistant to apoptosis, and consequently accumulate to the detriment of normal B cells and patient immunity. Because current therapies fail to eradicate these apoptosis-resistant cells, it is essential to identify alternative survival pathways as novel targets for anticancer therapies. Overexpression of cell-surface G protein-coupled receptors drives cell transformation, and thus plays a critical role in malignancies. In this study, we identified neurotensin receptor 2 (NTSR2) as an essential driver of apoptosis resistance in B-CLL. NTSR2 was highly expressed in B-CLL cells, whereas expression of its natural ligand, neurotensin (NTS), was minimal in both B-CLL cells and patient plasma. Surprisingly, NTSR2 remained in a constitutively active phosphorylated state, caused not by a mutation-induced gain-of-function but rather by an interaction with the oncogenic tyrosine kinase receptor TrkB. Functional and biochemical characterization revealed that the NTSR2-TrkB interaction acts as a conditional oncogenic driver requiring the TrkB ligand brain-derived neurotrophic factor (BDNF), which unlike NTS is highly expressed in B-CLL cells. Together, NTSR2, TrkB and BDNF induce autocrine and/or paracrine survival pathways that are independent of mutation status and indolent or progressive disease course. The NTSR2-TrkB interaction activates survival signaling pathways, including the Src and AKT kinase pathways, as well as expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL. When NTSR2 was downregulated, TrkB failed to protect B-CLL cells from a drastic decrease in viability via typical apoptotic cell death, reflected by DNA fragmentation and Annexin V presentation. Together, our findings demonstrate that the NTSR2-TrkB interaction plays a crucial role in B-CLL cell survival, suggesting that inhibition of NTSR2 represents a promising targeted strategy for treating B-CLL malignancy.
Collapse
Affiliation(s)
- A Abbaci
- Limoges University, Equipe Accueil 3842, Cellular Homeostasis and Diseases, Faculty of Medicine, Limoges Cedex, France
| | - H Talbot
- Limoges University, Equipe Accueil 3842, Cellular Homeostasis and Diseases, Faculty of Medicine, Limoges Cedex, France
| | - S Saada
- Limoges University, Equipe Accueil 3842, Cellular Homeostasis and Diseases, Faculty of Medicine, Limoges Cedex, France
| | - N Gachard
- Hematology Laboratory, Dupuytren Hospital University Center of Limoges, Limoges Cedex, France.,CNRS-UMR 7276, Limoges University, Limoges Cedex, France
| | - J Abraham
- Department of Hematology, Dupuytren Hospital University Center of Limoges, Limoges Cedex, France
| | - A Jaccard
- CNRS-UMR 7276, Limoges University, Limoges Cedex, France.,Department of Hematology, Dupuytren Hospital University Center of Limoges, Limoges Cedex, France
| | - D Bordessoule
- CNRS-UMR 7276, Limoges University, Limoges Cedex, France.,Department of Hematology, Dupuytren Hospital University Center of Limoges, Limoges Cedex, France
| | - A L Fauchais
- Limoges University, Equipe Accueil 3842, Cellular Homeostasis and Diseases, Faculty of Medicine, Limoges Cedex, France.,Department of Internal Medicine, Dupuytren Hospital University Center of Limoges, Limoges Cedex, France
| | - T Naves
- Limoges University, Equipe Accueil 3842, Cellular Homeostasis and Diseases, Faculty of Medicine, Limoges Cedex, France
| | - M O Jauberteau
- Limoges University, Equipe Accueil 3842, Cellular Homeostasis and Diseases, Faculty of Medicine, Limoges Cedex, France.,Department of Immunology, Dupuytren Hospital University Center of Limoges, Limoges Cedex, France
| |
Collapse
|
20
|
The role of G protein-coupled receptors in lymphoid malignancies. Cell Signal 2017; 39:95-107. [PMID: 28802842 DOI: 10.1016/j.cellsig.2017.08.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Revised: 08/04/2017] [Accepted: 08/07/2017] [Indexed: 12/20/2022]
Abstract
B cell lymphoma consists of multiple individual diseases arising throughout the lifespan of B cell development. From pro-B cells in the bone marrow, through circulating mature memory B cells, each stage of B cell development is prone to oncogenic mutation and transformation, which can lead to a corresponding lymphoma. Therapies designed against individual types of lymphoma often target features that differ between malignant cells and the corresponding normal cells from which they arise. These genetic changes between tumor and normal cells can include oncogene activation, tumor suppressor gene repression and modified cell surface receptor expression. G protein-coupled receptors (GPCRs) are an important class of cell surface receptors that represent an ideal target for lymphoma therapeutics. GPCRs bind a wide range of ligands to relay extracellular signals through G protein-mediated signaling cascades. Each lymphoma subgroup expresses a unique pattern of GPCRs and efforts are underway to fully characterize these patterns at the genetic level. Aberrations such as overexpression, deletion and mutation of GPCRs have been characterized as having causative roles in lymphoma and such studies describing GPCRs in B cell lymphomas are summarized here.
Collapse
|
21
|
Dong Z, Lei Q, Yang R, Zhu S, Ke XX, Yang L, Cui H, Yi L. Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma. Br J Cancer 2017; 116:1572-1584. [PMID: 28494471 PMCID: PMC5518855 DOI: 10.1038/bjc.2017.126] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Revised: 02/10/2017] [Accepted: 04/11/2017] [Indexed: 12/12/2022] Open
Abstract
Backgroud: Glioblastoma is a kind of highly malignant and aggressive tumours in the central nervous system. Previously, we found that neurotensin (NTS) and its high-affinity receptor 1 (NTSR1) had essential roles in cell proliferation and invasiveness of glioblastoma. Unexpectedly, cell death also appeared by inhibition of NTSR1 except for cell cycle arrest. However, the mechanisms were remained to be further explored. Methods: Cells treated with SR48692, a selective antagonist of NTSR1, or NTSR1 shRNA were stained with Annexin V-FITC/PI and the apoptosis was assessed by flow cytometry. Cytochrome c release was detected by using immunofluorescence. Mitochondrial membrane potential (MMP, ΔΨm) loss was stained by JC-1 and detected by immunofluorescence or flow cytometry. Apoptosis antibody array and microRNA microarray were performed to seek the potential regulators of NTSR1 inhibition-induced apoptosis. Interaction between let-7a-3p and Bcl-w 3′UTR was evaluated by using luciferase assay. Results: SR48692 induced massive apoptosis, which was related to mitochondrial cytochrome c release and MMP loss. Knockdown of NTSR1 induced slight apoptosis and significant MMP loss. In addition, NTSR1 inhibition sensitised glioblastoma cells to actinomycin D or doxorubicin-induced apoptosis. Consistently, NTSR1 inhibition-induced mitochondrial apoptosis was accompanied by downregulation of Bcl-w and Bcl-2. Restoration of Bcl-w partly rescued NTSR1 deficiency-induced apoptosis. In addition, NTSR1 deficiency promoted higher let-7a-3p expression and inhibition let-7a-3p partly rescued NTSR1 inhibition-induced apoptosis. In addition, let-7a-3p inhibition promoted 3′UTR activities of Bcl-w and the expression of c-Myc and LIN28, which were the upstream of let-7a-3p, decreased after NTSR1 inhibition. Conclusions: NTSR1 had an important role in protecting glioblastoma from intrinsic apoptosis via c-Myc/LIN28/let-7a-3p/Bcl-w axis.
Collapse
Affiliation(s)
- Zhen Dong
- State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400715, China
| | - Qian Lei
- State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400715, China
| | - Rui Yang
- State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400715, China
| | - Shunqin Zhu
- State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400715, China
| | - Xiao-Xue Ke
- State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400715, China
| | - Liqun Yang
- State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400715, China
| | - Hongjuan Cui
- State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400715, China
| | - Liang Yi
- State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400715, China.,Department of Neurosurgery, Daping Hospital, the Third Military Medical University, Chongqing 400042, China
| |
Collapse
|
22
|
Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: Targeting endothelin-1 receptor to control proliferation. Autoimmun Rev 2017; 16:398-406. [DOI: 10.1016/j.autrev.2017.02.006] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Accepted: 12/16/2016] [Indexed: 01/06/2023]
|
23
|
Simeth NA, Bause M, Dobmeier M, Kling RC, Lachmann D, Hübner H, Einsiedel J, Gmeiner P, König B. NTS2-selective neurotensin mimetics with tetrahydrofuran amino acids. Bioorg Med Chem 2017; 25:350-359. [DOI: 10.1016/j.bmc.2016.10.039] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Revised: 10/20/2016] [Accepted: 10/31/2016] [Indexed: 01/10/2023]
|
24
|
Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells. Oncotarget 2016; 6:26960-70. [PMID: 26298774 PMCID: PMC4694966 DOI: 10.18632/oncotarget.4745] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Accepted: 07/15/2015] [Indexed: 01/27/2023] Open
Abstract
Neurotensin (NTS), localized predominantly to the small bowel, stimulates the growth of a variety of cancers, including neuroendocrine tumors (NETs), mainly through its interaction with the high-affinity NTS receptor 1 (NTSR1). Here, we observed increased expression of NTSR1 in almost all tested clinical NET samples, but not in normal tissues. Through RT-PCR analysis, we found that the expression of NTSR1 and NTSR2 was either variable (NTSR1) or absent (NTSR2) in human NET cell lines. In contrast, NTSR3 and NTS were expressed in all NET cells. Treatment with 5-aza-2′-deoxycytidine, a demethylating agent, increased levels of NTSR1 and NTSR2 suggesting that DNA methylation contributes to NTSR1/2 expression patterns, which was confirmed by methylation analyses. In addition, we found that knockdown of NTSR1 decreased proliferation, expression levels of growth-related proteins, and anchorage-independent growth of BON human carcinoid cells. Moreover, stable silencing of NTSR1 suppressed BON cell growth, adhesion, migration and invasion. Our results show that high expression of NTSR1 is found in clinical NETs and that promoter methylation is an important mechanism controlling the differential expression of NTSR1 and silencing of NTSR2 in NET cells. Furthermore, knockdown of NTSR1 in BON cells suppressed oncogenic functions suggesting that NTSR1 contributes to NET tumorigenesis.
Collapse
|
25
|
Wang Q, Mao-Draayer Y. Interferon beta (IFN-β) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathway. Neural Regen Res 2016; 10:1932-3. [PMID: 26889174 PMCID: PMC4730810 DOI: 10.4103/1673-5374.169636] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- Qin Wang
- Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Yang Mao-Draayer
- Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA
| |
Collapse
|
26
|
Hillis J, O'Dwyer M, Gorman AM. Neurotrophins and B-cell malignancies. Cell Mol Life Sci 2016; 73:41-56. [PMID: 26399960 PMCID: PMC11108515 DOI: 10.1007/s00018-015-2046-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Revised: 08/26/2015] [Accepted: 09/14/2015] [Indexed: 12/12/2022]
Abstract
Neurotrophins and their receptors act as important proliferative and pro-survival factors in a variety of cell types. Neurotrophins are produced by multiple cell types in both pro- and mature forms, and can act in an autocrine or paracrine fashion. The p75(NTR) and Trk receptors can elicit signalling in response to the presence or absence of their corresponding neurotrophin ligands. This signalling, along with neurotrophin and receptor expression, varies between different cell types. Neurotrophins and their receptors have been shown to be expressed by and elicit signalling in B lymphocytes. In general, most neurotrophins are expressed by activated B-cells and memory B-cells. Likewise, the TrkB95 receptor is seen on activated B-cells, while TrkA and p75(NTR) are expressed by both resting and active B-cells as well as memory B-cells. Nerve growth factor stimulates B-cell proliferation, memory B-cell survival, antibody production and CD40 expression. Brain-derived neurotrophic factor is involved in B-cell maturation in the bone marrow through TrkB95. Overall neurotrophins and their receptors have been shown to be involved in B-cell proliferation, development, differentiation, antibody secretion and survival. As well as expression and activity in healthy B-cells, the neurotrophins and their receptors can contribute to B-cell malignancies including acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, Burkitt's lymphoma and multiple myeloma. They are involved in B-cell malignancy survival and potentially in drug resistance.
Collapse
MESH Headings
- Animals
- B-Lymphocytes/metabolism
- B-Lymphocytes/pathology
- Gene Expression Regulation, Neoplastic
- Humans
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/metabolism
- Lymphoma, B-Cell/pathology
- Lymphoma, Follicular/genetics
- Lymphoma, Follicular/metabolism
- Lymphoma, Follicular/pathology
- Multiple Myeloma/genetics
- Multiple Myeloma/metabolism
- Multiple Myeloma/pathology
- Nerve Growth Factors/analysis
- Nerve Growth Factors/genetics
- Nerve Growth Factors/metabolism
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology
- Receptors, Nerve Growth Factor/analysis
- Receptors, Nerve Growth Factor/genetics
- Receptors, Nerve Growth Factor/metabolism
- Signal Transduction
Collapse
Affiliation(s)
- Jennifer Hillis
- Apoptosis Research Centre, School of Natural Sciences, National University of Ireland, Galway, Ireland
| | - Michael O'Dwyer
- Apoptosis Research Centre, School of Natural Sciences, National University of Ireland, Galway, Ireland
- Haematology, University College Hospital, Galway, Ireland
| | - Adrienne M Gorman
- Apoptosis Research Centre, School of Natural Sciences, National University of Ireland, Galway, Ireland.
| |
Collapse
|
27
|
The Internalization of Neurotensin by the Low-Affinity Neurotensin Receptors (NTSR2 and vNTSR2) Activates ERK 1/2 in Glioma Cells and Allows Neurotensin-Polyplex Transfection of tGAS1. Cell Mol Neurobiol 2015; 35:785-95. [DOI: 10.1007/s10571-015-0172-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Accepted: 03/07/2015] [Indexed: 01/14/2023]
|
28
|
Ly KH, Régent A, Molina E, Saada S, Sindou P, Le-Jeunne C, Brézin A, Witko-Sarsat V, Labrousse F, Robert PY, Bertin P, Bourges JL, Fauchais AL, Vidal E, Mouthon L, Jauberteau MO. Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling. Arthritis Res Ther 2014; 16:487. [PMID: 25418464 PMCID: PMC4274683 DOI: 10.1186/s13075-014-0487-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2014] [Accepted: 11/10/2014] [Indexed: 01/08/2023] Open
Abstract
Introduction Giant cell arteritis (GCA) is characterized by intimal hyperplasia leading to ischaemic manifestations that involve large vessels. Neurotrophins (NTs) and their receptors (NTRs) are protein factors for growth, differentiation and survival of neurons. They are also involved in the migration of vascular smooth muscle cells (VSMCs). Our aim was to investigate whether NTs and NTRs are involved in vascular remodelling of GCA. Methods We included consecutive patients who underwent a temporal artery biopsy for suspected GCA. We developed an enzymatic digestion method to obtain VSMCs from smooth muscle cells in GCA patients and controls. Neurotrophin protein and gene expression and functional assays were studied from these VSMCs. Neurotrophin expression was also analysed by immunohistochemistry in GCA patients and controls. Results Whereas temporal arteries of both GCA patients (n = 22) and controls (n = 21) expressed nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), tropomyosin receptor kinase B (TrkB) and sortilin, immunostaining was more intense in GCA patients, especially in the media and intima, while neurotrophin-3 (NT-3) and P75 receptor (P75NTR) were only detected in TA from GCA patients. Expression of TrkB, a BDNF receptor, was higher in GCA patients with ischaemic complications. Serum NGF was significantly higher in GCA patients (n = 28) vs. controls (n = 48), whereas no significant difference was found for BDNF and NT-3. NGF and BDNF enhanced GCA-derived temporal artery VSMC proliferation and BDNF facilitated migration of temporal artery VSMCs in patients with GCA compared to controls. Conclusions Our results suggest that NTs and NTRs are involved in vascular remodelling of GCA. In GCA-derived temporal artery VSMC, NGF promoted proliferation and BDNF enhanced migration by binding to TrkB and p75NTR receptors. Further experiments are needed on a larger number of VSMC samples to confirm these results. Electronic supplementary material The online version of this article (doi:10.1186/s13075-014-0487-z) contains supplementary material, which is available to authorized users.
Collapse
|
29
|
Carlo AS, Nykjaer A, Willnow TE. Sorting receptor sortilin-a culprit in cardiovascular and neurological diseases. J Mol Med (Berl) 2014; 92:905-11. [PMID: 24838608 DOI: 10.1007/s00109-014-1152-3] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Accepted: 02/19/2014] [Indexed: 11/30/2022]
Abstract
Sortilin is a sorting receptor that directs target proteins, such as growth factors, signaling receptors, and enzymes, to their destined location in secretory or endocytic compartments of cells. The activity of sortilin is essential for proper function of not only neurons but also non-neuronal cell types, and receptor (dys)function emerges as a major cause of malignancies, including hypercholesterolemia, retinal degeneration, neuronal cell loss in stroke and spinal cord injury, or Alzheimer's disease and other neurodegenerative disorders. In this article, we describe the molecular mechanisms of sortilin action in protein sorting and signaling and how modulation of receptor function may offer novel therapeutic strategies for treatment of common diseases of the cardiovascular and nervous systems.
Collapse
Affiliation(s)
- Anne-Sophie Carlo
- Max-Delbrueck-Center for Molecular Medicine, Robert-Roessle-Strasse 10, 13125, Berlin, Germany
| | | | | |
Collapse
|
30
|
Hernandez ME, Rembao JD, Hernandez-Baltazar D, Castillo-Rodriguez RA, Tellez-Lopez VM, Flores-Martinez YM, Orozco-Barrios CE, Rubio HA, Sánchez-García A, Ayala-Davila J, Arango-Rodriguez ML, Pavón L, Mejia-Castillo T, Forgez P, Martinez-Fong D. Safety of the intravenous administration of neurotensin-polyplex nanoparticles in BALB/c mice. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2013; 10:745-54. [PMID: 24333586 DOI: 10.1016/j.nano.2013.11.013] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2013] [Revised: 10/14/2013] [Accepted: 11/20/2013] [Indexed: 11/15/2022]
Abstract
UNLABELLED Neurotensin (NTS)-polyplex is a gene nanocarrier that has potential nanomedicine-based applications for the treatment of Parkinson's disease and cancers of cells expressing NTS receptor type 1. We assessed the acute inflammatory response to NTS-polyplex carrying a reporter gene in BALB/c mice. The intravenous injection of NTS-polyplex caused the specific expression of the reporter gene in gastrointestinal cells. Six hours after an intravenous injection of propidium iodide labeled-NTS-polyplex, fluorescent spots were located in the cells of the organs with a mononuclear phagocyte system, suggesting NTS-polyplex clearance. In contrast to lipopolysaccharide and carbon tetrachloride, NTS-polyplex did not increase the serum levels of tumor necrosis factor alpha, interleukin (IL)-1β, IL-6, bilirubin, aspartate transaminase, and alanine transaminase. NTS-polyplex increased the levels of serum amyloid A and alkaline phosphatase, but these levels normalized after 24 h. Compared to carrageenan, the local injection of NTS-polyplex did not produce inflammation. Our results support the safety of NTS-polyplex. FROM THE CLINICAL EDITOR This study focuses on the safety of neurotensin (NTS)-polyplex, a gene nanocarrier that has potential in the treatment of Parkinson's disease and cancers of cells expressing NTS receptor type 1. NTS polyplex demonstrates a better safety profile compared with carrageenan, lipopolysaccharide, and carbon tetrachloride in a murine model.
Collapse
Affiliation(s)
| | | | | | | | - Victor M Tellez-Lopez
- Department of Physiology, Biophysics and Neurosciences, CINVESTAV-I.P.N., Mexico DF, Mexico
| | | | | | | | | | - Jose Ayala-Davila
- Department of Physiology, Biophysics and Neurosciences, CINVESTAV-I.P.N., Mexico DF, Mexico
| | - Martha L Arango-Rodriguez
- Instituto de Ciencias, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile
| | - Lenin Pavón
- Department of Psychoimmunology, INPRF, Mexico DF, Mexico
| | - Teresa Mejia-Castillo
- Department of Physiology, Biophysics and Neurosciences, CINVESTAV-I.P.N., Mexico DF, Mexico
| | | | - Daniel Martinez-Fong
- Department of Physiology, Biophysics and Neurosciences, CINVESTAV-I.P.N., Mexico DF, Mexico; PhD Program in Nanoscience and Nanotechnology; CINVESTAV-I.P.N., Mexico DF, Mexico.
| |
Collapse
|
31
|
Devader C, Béraud-Dufour S, Coppola T, Mazella J. The anti-apoptotic role of neurotensin. Cells 2013; 2:124-35. [PMID: 24709648 PMCID: PMC3972661 DOI: 10.3390/cells2010124] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2013] [Revised: 02/15/2013] [Accepted: 02/26/2013] [Indexed: 01/07/2023] Open
Abstract
The neuropeptide, neurotensin, exerts numerous biological functions, including an efficient anti-apoptotic role, both in the central nervous system and in the periphery. This review summarizes studies that clearly evidenced the protective effect of neurotensin through its three known receptors. The pivotal involvement of the neurotensin receptor-3, also called sortilin, in the molecular mechanisms of the anti-apoptotic action of neurotensin has been analyzed in neuronal cell death, in cancer cell growth and in pancreatic beta cell protection. The relationships between the anti-apoptotic role of neurotensin and important physiological and pathological contexts are discussed in this review.
Collapse
Affiliation(s)
- Christelle Devader
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UMR 7275, Université de Nice-Sophia Antipolis, 660 route des Lucioles, Valbonne 06560, France.
| | - Sophie Béraud-Dufour
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UMR 7275, Université de Nice-Sophia Antipolis, 660 route des Lucioles, Valbonne 06560, France
| | - Thierry Coppola
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UMR 7275, Université de Nice-Sophia Antipolis, 660 route des Lucioles, Valbonne 06560, France.
| | - Jean Mazella
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UMR 7275, Université de Nice-Sophia Antipolis, 660 route des Lucioles, Valbonne 06560, France.
| |
Collapse
|
32
|
Wu Z, Martinez-Fong D, Trédaniel J, Forgez P. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. Front Endocrinol (Lausanne) 2012; 3:184. [PMID: 23335914 PMCID: PMC3547287 DOI: 10.3389/fendo.2012.00184] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/23/2012] [Accepted: 12/26/2012] [Indexed: 12/12/2022] Open
Abstract
Cancer is a worldwide health problem. Personalized treatment represents a future advancement for cancer treatment, in part due to the development of targeted therapeutic drugs. These molecules are expected to be more effective than current treatments and less harmful to normal cells. The discovery and validation of new targets are the foundation and the source of these new therapies. The neurotensinergic system has been shown to enhance cancer progression in various cancers such as pancreatic, prostate, lung, breast, and colon cancer. It also triggers multiple oncogenic signaling pathways, such as the PKC/ERK and AKT pathways. In this review, we discuss the contribution of the neurotensinergic system to cancer progression, as well as the regulation and mechanisms of the system in order to highlight its potential as a therapeutic target, and its prospect for its use as a treatment in certain cancers.
Collapse
Affiliation(s)
- Zherui Wu
- INSERM-UPMC UMR_S938, Hôpital Saint-AntoineParis, France
| | - Daniel Martinez-Fong
- Departamento de Fisiologïa, Biofïsica y Neurociencias, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico NacionalMexico City, Mexico
| | - Jean Trédaniel
- INSERM-UPMC UMR_S938, Hôpital Saint-AntoineParis, France
- Unité de Cancérologie Thoracique, Groupe Hospitalier Paris Saint-Joseph/Université Paris DescartesParis, France
| | - Patricia Forgez
- INSERM-UPMC UMR_S938, Hôpital Saint-AntoineParis, France
- *Correspondence: Patricia Forgez, INSERM-UPMC UMR_S938, Hôpital Saint-Antoine, Bâtiment Raoul Kourilsky, 184 rue du Faubourg St-Antoine, 75571 Paris Cedex 12, France. e-mail:
| |
Collapse
|